U.S. pharma big copyright scrapped two experimental weight loss capsules past 12 months—a after-each day capsule, lotiglipron, as a result of elevated liver enzymes plus a two times-each day pill, danuglipron, due to strong Unintended effects—but CEO Albert Bourla has said the company is decided to “Perform and gain” in the weight problems